TABLE 1.
Clinicopathological characteristics of high- and low-MCTS1 expression groups.
| Characteristic | Levels | Low expression of MCTS1 | High expression of MCTS1 | p value |
|---|---|---|---|---|
| n | 532 | 533 | ||
| Age, median (IQR) | 57.5 (48, 65) | 59 (49, 69) | 0.048 | |
| Age, n (%) | ≤60 | 310 (29.1%) | 278 (26.1%) | 0.052 |
| >60 | 222 (20.8%) | 255 (23.9%) | ||
| T stage, n (%) | T1 | 146 (13.7%) | 129 (12.1%) | 0.292 |
| T2 | 306 (28.8%) | 309 (29.1%) | ||
| T3 | 65 (6.1%) | 72 (6.8%) | ||
| T4 | 13 (1.2%) | 22 (2.1%) | ||
| N stage, n (%) | N0 | 259 (24.8%) | 248 (23.7%) | 0.654 |
| N1 | 165 (15.8%) | 184 (17.6%) | ||
| N2 | 61 (5.8%) | 55 (5.3%) | ||
| N3 | 36 (3.4%) | 38 (3.6%) | ||
| M stage, n (%) | M0 | 448 (49.3%) | 441 (48.5%) | 0.043 |
| M1 | 5 (0.6%) | 15 (1.7%) | ||
| Pathologic stage, n (%) | Stage I | 99 (9.5%) | 81 (7.8%) | 0.050 |
| Stage II | 296 (28.4%) | 310 (29.8%) | ||
| Stage III | 122 (11.7%) | 116 (11.1%) | ||
| Stage IV | 4 (0.4%) | 14 (1.3%) | ||
| Race, n (%) | Asian | 20 (2%) | 40 (4.1%) | 0.005 |
| Black or African American | 83 (8.5%) | 96 (9.8%) | ||
| White | 392 (40.2%) | 345 (35.3%) | ||
| Histological type, n (%) | Infiltrating Ductal Carcinoma | 343 (35.8%) | 414 (43.2%) | < 0.001 |
| Infiltrating Lobular Carcinoma | 132 (13.8%) | 70 (7.3%) | ||
| PR status, n (%) | Negative | 180 (17.7%) | 158 (15.6%) | 0.404 |
| Indeterminate | 2 (0.2%) | 2 (0.2%) | ||
| Positive | 331 (32.6%) | 343 (33.8%) | ||
| ER status, n (%) | Negative | 119 (11.7%) | 118 (11.6%) | 0.970 |
| Indeterminate | 1 (0.1%) | 1 (0.1%) | ||
| Positive | 394 (38.7%) | 384 (37.8%) | ||
| HER2 status, n (%) | Negative | 294 (41%) | 254 (35.4%) | 0.139 |
| Indeterminate | 5 (0.7%) | 7 (1%) | ||
| Positive | 71 (9.9%) | 86 (12%) | ||
| PAM50, n (%) | Normal | 30 (2.8%) | 10 (0.9%) | < 0.001 |
| Luminal A | 294 (27.6%) | 257 (24.1%) | ||
| Luminal B | 79 (7.4%) | 123 (11.5%) | ||
| Her2 | 34 (3.2%) | 48 (4.5%) | ||
| Basal | 95 (8.9%) | 95 (8.9%) | ||
| Menopause status, n (%) | Pre | 126 (13.2%) | 98 (10.3%) | 0.130 |
| Peri | 18 (1.9%) | 21 (2.2%) | ||
| Post | 338 (35.4%) | 355 (37.1%) | ||
| Anatomic neoplasm subdivisions, n (%) | Left | 267 (25.1%) | 286 (26.9%) | 0.284 |
| Right | 265 (24.9%) | 247 (23.2%) | ||
| Radiation therapy, n (%) | No | 225 (23.1%) | 207 (21.3%) | 0.601 |
| Yes | 271 (27.9%) | 269 (27.7%) | ||
| OS event, n (%) | Alive | 479 (45%) | 439 (41.2%) | < 0.001 |
| Dead | 53 (5%) | 94 (8.8%) | ||
| DSS event, n (%) | Alive | 498 (47.6%) | 467 (44.6%) | 0.002 |
| Dead | 27 (2.6%) | 54 (5.2%) |
Abbreviations: ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; OS, overall survival; DSS, disease-specific survival.
Bold values denote two-sided p < 0.05.